Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Search

Page Path
HOME > Search
1 "Eun-Ju Do"
Filter
Filter
Article category
Keywords
Publication year
Authors
More +
Original Article
Lung and Thoracic cancer
A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer
Eo Jin Kim, Yong-Hee Cho, Dong Ha Kim, Dae-Hyun Ko, Eun-Ju Do, Sang-Yeob Kim, Yong Man Kim, Jae Seob Jung, Yoonmi Kang, Wonjun Ji, Myeong Geun Choi, Jae Cheol Lee, Jin Kyung Rho, Chang-Min Choi
Cancer Res Treat. 2022;54(4):1005-1016.   Published online December 3, 2021
DOI: https://doi.org/10.4143/crt.2021.986
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The aim of this study is to evaluate the safety and efficacy of ex vivo activated and expanded natural killer (NK) cell therapy (SNK01) plus pembrolizumab in a randomized phase I/IIa clinical trial.
Materials and Methods
Overall, 18 patients with advanced non–small cell lung cancer (NSCLC) and a programmed death ligand 1 tumor proportion score of 1% or greater who had a history of failed frontline platinum-based therapy were randomized (2:1) to receive pembrolizumab every 3 weeks +/– 6 weekly infusions of SNK01 at either 2×109 or 4×109 cells per infusion (pembrolizumab monotherapy vs. SNK01 combination). The primary endpoint was safety, whereas the secondary endpoints were the objective response rate (ORR), progression-free survival (PFS), overall survival, and quality of life.
Results
Since no dose-limiting toxicity was observed, the maximum tolerated dose was determined as SNK01 4×109 cells/dose. The safety data did not show any new safety signals when SNK01 was combined with pembrolizumab. The ORR and the 1-year survival rate in the NK combination group were higher than those in patients who underwent pembrolizumab monotherapy (ORR, 41.7% vs. 0%; 1-year survival rate, 66.7% vs. 50.0%). Furthermore, the median PFS was higher in the SNK01 combination group (6.2 months vs. 1.6 months, p=0.001).
Conclusion
Based on the findings of this study, the NK cell combination therapy may consider as a safe treatment method for stage IV NSCLC patients who had a history of failed platinum-based therapy without an increase in adverse events.

Citations

Citations to this article as recorded by  
  • Cell therapy in sarcoma: current landscape and future directions
    Taha Koray Sahin, Theodora Germetaki, Deniz Can Guven, Serkan Akin, Omer Dizdar, Fiona Thistlethwaite, Elizabeth A Connolly, Kok Haw Jonathan Lim
    Journal for ImmunoTherapy of Cancer.2026; 14(1): e013396.     CrossRef
  • NK cell infusion is well-tolerated and shows preliminary efficacy in patients with recurrent hepatocellular carcinoma post-liver transplantation : a phase I trial
    Fan Yang, Yihang Gong, Xiaofang Zheng, Beibei Ni, Jianxi Lu, Xiaoyan Chen, Jintao Cheng, Panlong Li, Cong Du, Yunhao Chen, Yingcai Zhang, Shuhong Yi, Guoying Wang, Qi Zhang, Yang Yang, Wenjie Chen
    Journal of Translational Medicine.2026;[Epub]     CrossRef
  • Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature review
    Lucie Biard, Vincent Lévy, Sylvie Chevret, Annette Künkele, Stefanie Grunwald, Alessandro Aiuti, Bjarne Kuno Møller, Reno Debets, Stephan Mielke, Johan van Eldere, Antonia Müller, Silvia Martin Lluesma, Lorena Consolino, Matt Bolz-Johnson, Stefano Benvenu
    Molecular Therapy Advances.2026; 34(1): 201651.     CrossRef
  • Human natural killer cells exhibit potent antifungal activity against azole-resistant Aspergillus fumigatus and diverse filamentous fungi
    Hotaka Namie, Takahiro Takazono, Satoshi Irifune, Satoru Koga, Yuya Ito, Nana Nakada, Tatsuro Hirayama, Masataka Yoshida, Kazuaki Takeda, Shotaro Ide, Naoki Iwanaga, Masato Tashiro, Naoki Hosogaya, Noriho Sakamoto, Haruki Okamura, Yoshimasa Tanaka, Katsun
    Microbiology Spectrum.2026;[Epub]     CrossRef
  • Cellular Therapies in Solid Tumors: Are We Ready for Primetime?
    Giuseppe Maiocco, Vinicius Ernani, Michael P. Gustafson, Salman R. Punekar, Konstantinos Leventakos, Julian Molina, Yousef Zakharia, Mitesh Borad, Antonious Z. Hazim
    JCO Oncology Practice.2026;[Epub]     CrossRef
  • Treatment of Alzheimer's Disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study
    Clemente Humberto Zúñiga, Blanca Isaura Acosta, Rufino Menchaca, Cesar A. Amescua, Sean Hong, Lucia Hui, Minchan Gil, Yong-hee Rhee, Sangwook Yoon, Minji Kim, Paul Y. Chang, Yong Man Kim, Paul Y. Song, Katia Betito
    Alzheimer's Research & Therapy.2025;[Epub]     CrossRef
  • Adopting tomorrow’s therapies today: a perspective review of adoptive cell therapy in lung cancer
    Faith Abodunrin, Daniel J Olson, Oluwatosin Emehinola, Christine M Bestvina
    Therapeutic Advances in Medical Oncology.2025;[Epub]     CrossRef
  • Preclinical investigation of anti-tumor efficacy of allogeneic natural killer cells combined with cetuximab for head and neck squamous cell carcinoma
    Chaeyeon Kim, Mina Han, Gamin Kim, Wonrak Son, Jeongah Kim, Minchan Gil, Yong-Hee Rhee, Nam Suk Sim, Chang Gon Kim, Hye Ryun Kim
    Cancer Immunology, Immunotherapy.2025;[Epub]     CrossRef
  • Harnessing Immune Rejuvenation: Advances in Overcoming T Cell Senescence and Exhaustion in Cancer Immunotherapy
    Tesfahun Dessale Admasu, John S. Yu
    Aging Cell.2025;[Epub]     CrossRef
  • Cytokines in Focus: IL-2 and IL-15 in NK Adoptive Cell Cancer Immunotherapy
    Bryan Marr, Donghyeon Jo, Mihue Jang, Seung-Hwan Lee
    Immune Network.2025;[Epub]     CrossRef
  • The updated network meta-analysis of the therapeutic efficacies of lung cancer: A systematic review and meta-analysis
    Chuan-Hsin Chang, Chih-Cheng Chien, Yue-Cune Chang
    Tzu Chi Medical Journal.2025; 37(3): 339.     CrossRef
  • Synergistic Anti-Tumor Efficacy of Modified FOLFIRINOX and NK Cell Therapy in Pancreatic Ductal Adenocarcinoma
    Hye-Seong Park, Jun Eul Hwang, Je-Jung Lee, Woo Kyun Bae
    Cancers.2025; 17(17): 2785.     CrossRef
  • Machine learning-based development of a cytotoxicity prediction model for NK cell therapy in cancers
    Jie Ma, Jingjing Yue, Yangyang Li, Yutong Li, Hongbo Dong, Fang Fang, Weihua Xiao
    Cellular Oncology.2025; 48(6): 1837.     CrossRef
  • Efficacy and safety of natural killer cell therapy for the treatment of advanced non-small cell lung cancer: A meta-analysis and systematic review
    Zhengnan Li, Xiu’e Wang, Shaoqing Chen, Ping Zhang, Xiujuan Wang, Xinye Ni, Chunlin Mou
    Immunologic Research.2025;[Epub]     CrossRef
  • Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical st
    Myeong Geun Choi, Gun Woo Son, Mi Young Choi, Jae Seob Jung, Jin Kyung Rho, Wonjun Ji, Byeong Gon Yoon, Jong-Min Jo, Yong Man Kim, Dae-Hyun Ko, Jae Cheol Lee, Chang-Min Choi
    Journal for ImmunoTherapy of Cancer.2024; 12(3): e008585.     CrossRef
  • Disruption of TGF-β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells
    Jaya Lakshmi Thangaraj, Michael Coffey, Edith Lopez, Dan S. Kaufman
    Cell Stem Cell.2024; 31(9): 1327.     CrossRef
  • Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
    Xin Su, Jian Li, Xiao Xu, Youbao Ye, Cailiu Wang, Guanglong Pang, Wenxiu Liu, Ang Liu, Changchun Zhao, Xiangyong Hao
    Journal of Translational Medicine.2024;[Epub]     CrossRef
  • Epigenetic regulation of NKG2D ligand and the rise of NK cell-based immunotherapy for cancer treatment
    Raj Kumar, Romi Gupta
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis
    Heesook Park, Gyurin Kim, Najin Kim, Sungyoen Ha, Hyeonwoo Yim
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Next-generation immunotherapy: igniting new hope for lung cancer
    Molly S. C. Li, Andrew L. S. Chan, Kevin K. S. Mok, Landon L. Chan, Tony S. K. Mok
    Therapeutic Advances in Medical Oncology.2024;[Epub]     CrossRef
  • Engineered Cellular Therapies for the Treatment of Thoracic Cancers
    Spencer M. Erickson, Benjamin M. Manning, Akhilesh Kumar, Manish R. Patel
    Cancers.2024; 17(1): 35.     CrossRef
  • Cellular Therapy in NSCLC: Between Myth and Reality
    Martina Imbimbo, Laureline Wetterwald, Alex Friedlaender, Kaushal Parikh, Alfredo Addeo
    Current Oncology Reports.2023; 25(10): 1161.     CrossRef
  • NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
    Sara Witting Christensen Wen, Line Nederby, Rikke Fredslund Andersen, Torben Schjødt Hansen, Christa Haugaard Nyhus, Ole Hilberg, Anders Jakobsen, Torben Frøstrup Hansen
    British Journal of Cancer.2023; 129(1): 135.     CrossRef
  • Harnessing Natural Killer Cells for Lung Cancer Therapy
    Shoubao Ma, Michael A. Caligiuri, Jianhua Yu
    Cancer Research.2023; 83(20): 3327.     CrossRef
  • Natural killer cells: the next wave in cancer immunotherapy
    Xin Chen, Lei Jiang, Xuesong Liu
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • 16,441 View
  • 623 Download
  • 24 Web of Science
  • 25 Crossref
Close layer
Cancer Res Treat : Cancer Research and Treatment
© Korean Cancer Association.
Close layer
TOP